NDA 215033 · Apotex
Bendamustine Hydrochloride
Bendamustine Hydrochloride · Intravenous
Last checked: Nov 20, 2026Latest source record: Apr 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 7, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
426
81 Phase 3, 51 recruiting
FAERS reports
7,951
7,612 serious, 1,554 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 9, 2026.
Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine hydrochloride injection is an alkylating drug indicated for treatment of adult patients with: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )
Mechanism: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BENDAMUSTINE HYDROCHLORIDE · BENDAMUSTINE HYDROCHLORIDE 100MG/4ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01332968 · 1,401 participants · Start Jul 6, 2011 · Primary completion Feb 1, 2016
Drug: Obinutuzumab; Cyclophosphamide and 5 more · For: Non-Hodgkin's Lymphoma
Sites: Springdale, Arkansas; Irvine, California; Post Falls, Idaho · 183 sites in all
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasPivotal-lookingStatus unknown
Jurgen BarthAcademic, hospital or other
NCT00877214 · 1,272 participants · Start Apr 1, 2009 · Primary completion Dec 2024
Drug: Rituximab; Rituximab / observation · For: Follicular Lymphomas; Immunocytomas; Marginal Zone Lymphomas and 3 more
Sites: Giessen, Germany
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT06191744 · 1,095 participants · Start Feb 5, 2024 · Primary completion Nov 2037
Drug: Epcoritamab; Prednisone and 7 more · For: Follicular Lymphoma (FL)
Sites: Fresno, California; San Diego, California; Santa Barbara, California · 266 sites in all
- Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT01476787 · 1,030 participants · Start Dec 29, 2011 · Primary completion Apr 30, 2024
Drug: Rituximab; Lenalidomide and 3 more · For: Follicular Lymphoma
Sites: Chandler, Arizona; Fullerton, California; Los Angeles, California · 36 sites in all
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT01650701 · 1,030 participants · Start Feb 2012 · Primary completion May 31, 2017
Drug: Rituximab; Lenalidomide and 3 more · For: Follicular Lymphoma
Sites: Concord, Australia; Penrith, Australia; Wollongong, Australia · 35 sites in all
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06549595 · 1,018 participants (planned) · Start Aug 7, 2024 · Primary completion Nov 26, 2031
Drug: Surovatamig; R-CHOP and 2 more · For: Untreated Follicular Lymphoma
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 244 sites in all
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT03836261 · 984 participants · Start Feb 25, 2019 · Primary completion Apr 30, 2027
Drug: Acalabrutinib; Venetoclax and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Los Angeles, California; Redondo Beach, California; Fort Wayne, Indiana · 169 sites in all
- A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic LeukemiaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01905943 · 979 participants · Start Nov 4, 2013 · Primary completion Dec 29, 2016
Drug: Bendamustine; Chlorambucil and 3 more · For: Chronic Lymphocytic Leukemia
Sites: Santa Fe, Argentina; Brussels, Belgium; Hasselt, Belgium · 174 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use995
- pyrexia555
- disease progression510
- covid-19406
- product use in unapproved indication400
- drug ineffective392
- febrile neutropenia366
- malignant neoplasm progression362
- neutrophil count decreased354
- neutropenia344
- platelet count decreased342
- pneumonia341
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 15 |
| 2012 | 129 |
| 2013 | 46 |
| 2014 | 267 |
| 2015 | 423 |
| 2016 | 435 |
| 2017 | 400 |
| 2018 | 594 |
| 2019 | 583 |
| 2020 | 607 |
| 2021 | 731 |
| 2022 | 1,445 |
| 2023 | 1,011 |
| 2024 | 735 |
| 2025 | 294 |
| 2026 | 230 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Sharman JP, Munir T, Grosicki S, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, et al. · J Clin Oncol 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, et al. · Lancet 2013 · Clinical Trial, Phase III, Comparative Study
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.